Viralgen Vector Core and Elpida Therapeutics have joined forces to manufacture gene therapies for use in clinical trials sponsored by Elpida Tx involving patients living with Spastic Paraplegia 50 (SPG50) or Charcot-Marie-Tooth disease type 4J (CMT4J). The trials will take place at various sites in North America and Europe and will explore potential safety and efficacy of the new treatments to be manufactured, as well as potential quality of life improvements. SPG50 is a rare disease caused b...